Primary Budd-Chiari syndrome

Journal of Hepatology

Volumn 50, Issue 1, 2009, Pages 195-203

  Valla, Dominique Charles ^a,b  

^a BEAUJON HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Anticoagulation; Liver transplantation; Myeloproliferative disease; Thrombophilia; Thrombosis; TIPS

Indexed keywords

ANTIVITAMIN K; HEPARIN; JANUS KINASE 2;

BONE MARROW BIOPSY; BUDD CHIARI SYNDROME; CANCER SURVIVAL; CLINICAL FEATURE; DISEASE COURSE; DISEASE SEVERITY; DOPPLER FLOWMETRY; DRUG EFFICACY; GENE MUTATION; HEALTH SURVEY; HEPATIC VEIN; HUMAN; INCIDENCE; INFERIOR CAVA VEIN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MYELOPROLIFERATIVE DISORDER; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL CONTRACEPTION; PATHOGENESIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PORTAL HYPERTENSION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; REVIEW; RISK FACTOR; STRUCTURED QUESTIONNAIRE; THROMBOCYTOPENIA; THROMBOSIS; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; TREATMENT OUTCOME;

ANGIOPLASTY; BUDD-CHIARI SYNDROME; DIURETICS; HEPATIC VEINS; HUMANS; JANUS KINASE 2; LIVER TRANSPLANTATION; MUTATION; REGIONAL BLOOD FLOW;

EID: 57049164801     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.10.007     Document Type: Review

References (56)

1. Janssen H.L., Garcia-Pagan J.C., Elias E., Mentha G., Hadengue A., and Valla D.C. Budd-Chiari syndrome: a review by an expert panel. J Hepatol 38 (2003) 364-371
2. Okuda H., Yamagata H., Obata H., Iwata H., Sasaki R., Imai F., et al. Epidemiological and clinical features of Budd-Chiari syndrome in Japan. J Hepatol 22 (1995) 1-9
3. Valla D. Hepatic venous outflow tract obstruction etipathogenesis: Asia versus the West. J Gastroenterol Hepatol 19 (2004) S204-S211
4. Shrestha S.M., Okuda K., Uchida T., Maharjan K.G., Shrestha S., Joshi B.L., et al. Endemicity and clinical picture of liver disease due to obstruction of the hepatic portion of the inferior vena cava in Nepal. J Gastroenterol Hepatol 11 (1996) 170-179
5. Amarapurkar D.N., Punamiya S.J., and Patel N.D. Changing spectrum of Budd-Chiari syndrome in India with special reference to non-surgical treatment. World J Gastroenterol 14 (2008) 278-285
6. Dilawari J.B., Bambery P., Chawla Y., Kaur U., Bhusnurmath S.R., Malhotra H.S., et al. Hepatic outflow obstruction (Budd-Chiari syndrome). Experience with 177 patients and a review of the literature. Medicine (Baltimore) 73 (1994) 21-36
7. Darwish Murad S., Plessier A., Hernandez-Guerra M., Primignani M., Elias E., Bahr M., et al. A prospective follow-up study on 163 patients with Budd-Chiari syndrome: results from the european network for vascular disorders of the Liver (EN-Vie). J Hepatol 46 (2007) S4
8. Okuda K. Inferior vena cava thrombosis at its hepatic portion (obliterative hepatocavopathy). Semin Liver Dis 22 (2002) 15-26
9. Valla D., Hadengue A., el Younsi M., Azar N., Zeitoun G., Boudet M.J., et al. Hepatic venous outflow block caused by short-length hepatic vein stenoses. Hepatology 25 (1997) 814-819
10. Denninger M.H., Chait Y., Casadevall N., Hillaire S., Guillin M.C., Bezeaud A., et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology 31 (2000) 587-591
11. Janssen H.L., Meinardi J.R., Vleggaar F.P., van Uum S.H., Haagsma E.B., van Der Meer F.J., et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 96 (2000) 2364-2368
12. Primignani M., Barosi G., Bergamaschi G., Gianelli U., Fabris F., Reati R., et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 44 (2006) 1528-1534
13. Mercier E., Lissalde-Lavigne G., and Gris J.C. JAK2 V617F mutation in unexplained loss of first pregnancy. N Engl J Med 357 (2007) 1984-1985
14. James C., Ugo V., Le Couedic J.P., Staerk J., Delhommeau F., Lacout C., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 (2005) 1144-1148
15. Hussein K., Bock O., and Kreipe H. Histological and molecular classification of chronic myeloproliferative disorders in the Age of JAK2: persistence of old questions despite new answers. Pathobiology 74 (2007) 72-80
16. De Stefano V., Fiorini A., Rossi E., Za T., Farina G., Chiusolo P., et al. Prevalence of the JAK2(V617F) mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 5 (2007) 708-714
17. Kiladjian J.J., Cervantes F., Leebeek F.W.G., Chevret S., Cazals-Hatem D., Plessier A., et al. Role of JAK2 mutation detection in Budd-Chiari syndrome and portal vein thrombosis associated to MPD. Blood 106 (2006) 377
18. Regina S., Herault O., D'Alteroche L., Binet C., and Gruel Y. JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. J Thromb Haemost 5 (2007) 859-861
19. Colaizzo D., Amitrano L., Iannaccone L., Vergura P., Cappucci F., Grandone E., et al. Gain-of-function gene mutations and venous thromboembolism: distinct roles in different clinical settings. J Med Genet 44 (2007) 412-416
20. Patel R.K., Lea N.C., Heneghan M.A., Westwood N.B., Milojkovic D., Thanigaikumar M., et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 130 (2006) 2031-2038
21. Chait Y., Condat B., Cazals-Hatem D., Rufat P., Atmani S., Chaoui D., et al. Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol 129 (2005) 553-560
22. Bismuth E., Hadengue A., Hammel P., and Benhamou J.P. Hepatic vein thrombosis in Behcet's disease. Hepatology 11 (1990) 969-974
23. Bayraktar Y., Balkanci F., Bayraktar M., and Calguneri M. Budd-Chiari syndrome: a common complication of Behcet's disease. Am J Gastroenterol 92 (1997) 858-862
24. Hillmen P., Muus P., Duhrsen U., Risitano A.M., Schubert J., Luzzatto L., et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 110 (2007) 4123-4128
25. Hillmen P., Young N.S., Schubert J., Brodsky R.A., Socie G., Muus P., et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355 (2006) 1233-1243
26. Mangia A., Margaglione M., Cascavilla I., Gentile R., Cappucci G., Facciorusso D., et al. Anticardiolipin antibodies in patients with liver disease. Am J Gastroenterol 94 (1999) 2983-2987
27. Bosy-Westphal A., Ruschmeyer M., Czech N., Oehler G., Hinrichsen H., Plauth M., et al. Determinants of hyperhomocysteinemia in patients with chronic liver disease and after orthotopic liver transplantation. Am J Clin Nutr 77 (2003) 1269-1277
28. Valla D., Le M.G., Poynard T., Zucman N., Rueff B., and Benhamou J.P. Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives. A case-control study. Gastroenterology 90 (1986) 807-811
29. Kew M.C., McKnight A., Hodkinson J., Bukofzer S., and Esser J.D. The role of membranous obstruction of the inferior vena cava in the etiology of hepatocellular carcinoma in Southern African blacks. Hepatology 9 (1989) 121-125
30. Deltenre P., Denninger M.H., Hillaire S., Guillin M.C., Casadevall N., Briere J., et al. Factor V Leiden related Budd-Chiari syndrome. Gut 48 (2001) 264-268
31. Valla D.C. Thrombosis and anticoagulation in liver disease. Hepatology 47 (2008) 1384-1393
32. Rosendaal F.R. Venous thrombosis: the role of genes, environment, and behavior. Hematology Am Soc Hematol Educ Program 1-12 (2005)
33. Bezemer I.D., Bare L.A., Doggen C.J., Arellano A.R., Tong C., Rowland C.M., et al. Gene variants associated with deep vein thrombosis. Jama 299 (2008) 1306-1314
34. Hadengue A., Poliquin M., Vilgrain V., Belghiti J., Degott C., Erlinger S., et al. The changing scene of hepatic vein thrombosis: recognition of asymptomatic cases. Gastroenterology 106 (1994) 1042-1047
35. Griffith J.F., Mahmoud A.E., Cooper S., Elias E., West R.J., and Olliff S.P. Radiological intervention in Budd-Chiari syndrome: techniques and outcome in 18 patients. Clin Radiol 51 (1996) 775-784
36. Langlet P., Escolano S., Valla D., Coste-Zeitoun D., Denie C., Mallet A., et al. Clinicopathological forms and prognostic index in Budd-Chiari syndrome. J Hepatol 39 (2003) 496-501
37. Moucari R., Rautou P.E., Cazals-Hatem D., Geara A., Bureau C., Consigny Y., et al. Hepatocellular carcinoma in Budd-Chiari syndrome: characteristics and risk factors. Gut 57 (2008) 828-835
38. Parker R.G.F. Occlusion of the hepatic veins in man. Medicine (Baltimore) 38 (1959) 369-402
39. Cazals-Hatem D., Vilgrain V., Genin P., Denninger M.H., Durand F., Belghiti J., et al. Arterial and portal circulation and parenchymal changes in Budd-Chiari syndrome: a study in 17 explanted livers. Hepatology 37 (2003) 510-519
40. Murad S.D., Valla D.C., de Groen P.C., Zeitoun G., Haagsma E.B., Kuipers E.J., et al. Pathogenesis and treatment of Budd-Chiari syndrome combined with portal vein thrombosis. Am J Gastroenterol 101 (2006) 83-90
41. Paradis V., Bieche I., Dargere D., Cazals-Hatem D., Laurendeau I., Saada V., et al. Quantitative gene expression in Budd-Chiari syndrome: a molecular approach to the pathogenesis of the disease. Gut 54 (2005) 1776-1781
42. Miller W.J., Federle M.P., Straub W.H., and Davis P.L. Budd-Chiari syndrome: imaging with pathologic correlation. Abdom Imaging 18 (1993) 329-335
43. Tavill A.S., Wood E.J., Kreel L., Jones E.A., Gregory M., and Sherlock S. The Budd-Chiari syndrome: correlation between hepatic scintigraphy and the clinical, radiological, and pathological findings in nineteen cases of hepatic venous outflow obstruction. Gastroenterology 68 (1975) 509-518
44. de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 43 (2005) 167-176
45. Plessier A., Sibert A., Consigny Y., Hakime A., Zappa M., Denninger M.H., et al. Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome. Hepatology 44 (2006) 1308-1316
46. Primignani M., Dell' Era A., Fabris F.M., Reati R., Artoni A., and Mannucci P.M. High incidence of heparin-induced thrombocythemia (HIT) in splanchnic vein thrombosis treated with low molecular weight heparin 5LMWH. J Hepatol 48 (2008) S113
47. Eapen C.E., Velissaris D., Heydtmann M., Gunson B., Olliff S., and Elias E. Favourable medium term outcome following hepatic vein recanalisation and/or transjugular intrahepatic portosystemic shunt for Budd Chiari syndrome. Gut 55 (2006) 878-884
48. Hernandez-Guerra M., Turnes J., Rubinstein P., Olliff S., Elias E., Bosch J., et al. PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome. Hepatology 40 (2004) 1197-1202
49. Perello A., Garcia-Pagan J.C., Gilabert R., Suarez Y., Moitinho E., Cervantes F., et al. TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. Hepatology 35 (2002) 132-139
50. Murad S.D., Valla D.C., de Groen P.C., Zeitoun G., Hopmans J.A., Haagsma E.B., et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology 39 (2004) 500-508
51. Garcia-Pagan J.C., Heydtmann M., Raffa S., Plessier A., Murad S., Fabris F., et al. TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology 135 (2008) 808-815
52. Mentha G., Giostra E., Majno P.E., Bechstein W.O., Neuhaus P., O'Grady J., et al. Liver transplantation for Budd-Chiari syndrome: a European study on 248 patients from 51 centres. J Hepatol 44 (2006) 520-528
53. Segev D.L., Nguyen G.C., Locke J.E., Simpkins C.E., Montgomery R.A., Maley W.R., et al. Twenty years of liver transplantation for Budd-Chiari syndrome: a national registry analysis. Liver Transpl 13 (2007) 1285-1294
54. Valla D.C. The diagnosis and management of the Budd-Chiari syndrome: consensus and controversies. Hepatology 38 (2003) 793-803
55. Primignani M., Martinelli I., Bucciarelli P., Battaglioli T., Reati R., Fabris F., et al. Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology 41 (2005) 603-608
56. Colaizzo D., Amitrano L., Tiscia G.L., Scenna G., Grandone E., Guardascione M.A., et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 5 (2007) 55-61